Primary hyperaldosternism associated with hypertensive emergencies

American Journal of Hypertension

Volumn 19, Issue 6, 2006, Pages 623-627

  Labinson, Paul T ^a   White, William B ^a   Tendler, Beatriz E ^a   Mansoor, George A ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; POTASSIUM; RENIN;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BLOOD; CASE REPORT; DIFFERENTIAL DIAGNOSIS; EMERGENCY HEALTH SERVICE; FEMALE; HUMAN; HYPERALDOSTERONISM; MALE; MIDDLE AGED; RENOVASCULAR HYPERTENSION;

ACUTE DISEASE; ADULT; AGED; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; DIAGNOSIS, DIFFERENTIAL; EMERGENCY MEDICAL SERVICES; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION, RENAL; MALE; MIDDLE AGED; POTASSIUM; RENIN;

EID: 33646840171     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2005.12.011     Document Type: Article

References (26)

1. Conn JW: Presidential address. Part i. Painting background. Part ii. Primary aldosteronism: a new clinical syndrome. J Lab Clin Med 1955; 45: 3-17.
2. Melby JC: Diagnosis and treatment of primary aldosteronism and isolated hypo-aldosteronism. Clin Endocrinol Metab 1985; 14: 977-995.
3. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr: Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents J Clin Endocrinol Metab 2004;89:1045-1050. (Pubitemid 38368386)
4. Mulatero P, Dluhy RG, Giacchetti G, Boscaro M, Veglio F, Stewart PM: Diagnosis of primary aldosteronism: from screening to subtype differentiation. Tren Endocrinol Metab 2005;16:114-119. (Pubitemid 40432461)
5. Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiyama T: A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Int Med 1981;141:1589-1593. (Pubitemid 12234064)
6. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan ED Jr, Sos TA, Atlas SA, Muller FB, Acevedo R, Ulick S, Laragh JH: Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121: 877-885.
7. Conn JW, Knopf RF, Nesbit RM: Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 1964; 107: 159.
8. Zarifis J, Lip G, Leatherdale B, Beevers G: Malignant hypertension in association with primary aldosteronism. Blood Press 1996;5: 250-254. (Pubitemid 26235303)
9. Hall WD: Resistant hypertension, secondary hypertension and hypertensive crises. Cardiol Clin 2002; 20: 281-289.
10. Brill GC, Creamer B, Mills IH, Pullan JM: Hyperaldosteronism: report of a case. BmJ 1960; 2: 990-991.
11. Aloia J, Beutow G: Malignant hypertension with aldosteronoma producing adenoma. Am J Med Sci 1974; 268: 241-245.
12. Murphy BF, Whiteworth JA, Kincaid-Smith P: Malignant hypertension due to aldosterone producing adrenal adenoma. Clin Exp Hypertens A 1985;7:939-950. (Pubitemid 15005049)
13. Sunman W, Rothwell M, Sever PS: Conn's syndrome can cause malignant hypertension. J Hum Hypertens 1992; 6: 75-76.
14. Bortolotto LA, Cesena FH, Jatene FB, Silva HB: Malignant hypertension and hypertensive encephalopathy in primary aldosteronism caused by adrenal adenoma. Arq Bras Cardiol 2003; 81: 97-100.
15. Del Greco F, Dolkart R, Skom J, Method H: Association of accelerated (malignant) hypertension in a patient with primary aldosteronism. J Clin Endocrinol Metab 1966; 26: 808-814.
16. Baxter RH, Wang I: Malignant hypertension in a patient with Conn's syndrome. Scott Med J 1974; 19: 161-163.
17. Kaplan NM: Primary aldosteronism with malignant hypertension. N Engl J Med 1963; 269: 1282-1286.
18. Luetscher JA: Primary hyperaldosterouism: observations in 6 cases and review of diagnostic procedures. Medicine (Baltimore) 1964; 43: 137-157.
19. Oka K, Hayashi K, Nakazato T, Suzawa T, Fujiwara K, Saruta T: Malignant hypertension in a patient with primary aldosteronism with elevated active renin concentration. Intern Med 1997;36: 700-704. (Pubitemid 127515260)
20. Ideishi M, Kishikawa K, Kinoshita M, Sasaguri M, Ikeda M, Takebayashi S, Arakawa K: High-renin malignant hypertension secondary to an aldosteorne producing adenoma. Nephron 1990:54:259-263. (Pubitemid 20039693)
21. Iwaoka T, Umeda T, Sato T, Katsuragi S, Takeuchi T: High plasma renin activities in primary aldosteronism with malignant hypertension. Jpn Heart J 1980:21; 423-428. (Pubitemid 10082865)
22. Young WF. Primary aldosteronism: management issues. Ann NY Acad Sci 2002; 970: 61-76.
23. Doppmau JL, Gill JR. Jr, Miller DL, Chang R, Gupta R, Friedman TC, Choyke PL, Feuerstein IM, Dwyer AJ, Jicha DL. Distinction between hyperaldosteronism due to bilateral hyperplasia and unilateral aldosteronoma: reliability of CT. Radiology 1992; 184: 677-682.
24. Young WF: Minireview: primary aldosteronism-changing concepts in diagnosis and treatment. Endocrinology 2003; 144: 2208-2213.
25. Nishizaka MK, Zaman MA, Calhoun DA: Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16:925-930. (Pubitemid 37315491)
26. Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M: The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002;15:333-339. (Pubitemid 34408973)